Yoshimura Kiyoshi, Hazama Shoichi, Iizuka Norio, Takano Naofumi, Matsuoka Kohji, Tangoku Akira, Oka Masaaki
Dept. of Surgery II, Yamaguchi University School of Medicine.
Gan To Kagaku Ryoho. 2002 Nov;29(12):2117-20.
We administered interleukin (IL)-2 with mitomycin C (MMC) and 5-fluorouracil (5-FU) by hepatic arterial infusion for the treatment of liver recurrence from colorectal cancer. The regimen consisted of continuous hepatic arterial infusion of IL-2 (7 x 10(5) JRU/day)/5-FU (250 mg/day) for 4 weeks. After those 4 weeks, a weekly hepatic arterial infusion of IL-2 (2.1 x 10(6) JRU)/5-FU (250 mg) was performed more than 4 weeks. MMC (4 mg) was given as a bolus weekly. This therapy resulted in partial response (PR) in one case, progressive disease (PD) in one case, and no change (NC) in one case. The toxicity of the therapy was a slight in all cases. We herein report 3 patients treated with hepatic arterial infusion of IL-2 with MMC and 5-FU for liver recurrence from colorectal cancer. This therapy may be a new strategy for metastatic colorectal cancer.
我们通过肝动脉灌注给予白细胞介素(IL)-2联合丝裂霉素C(MMC)和5-氟尿嘧啶(5-FU),用于治疗结直肠癌肝转移复发。治疗方案包括连续4周肝动脉灌注IL-2(7×10⁵JRU/天)/5-FU(250mg/天)。这4周之后,接下来超过4周每周进行一次肝动脉灌注IL-2(2.1×10⁶JRU)/5-FU(250mg)。MMC(4mg)每周静脉推注一次。该治疗导致1例部分缓解(PR),1例疾病进展(PD),1例病情无变化(NC)。所有病例中治疗的毒性均较轻。我们在此报告3例接受肝动脉灌注IL-2联合MMC和5-FU治疗结直肠癌肝转移复发的患者。该治疗可能是转移性结直肠癌的一种新策略。